Sandra Levy
ARTICLES BY THIS AUTHOR
- 8/10/2022
Report: Digestive health products market to reach $89.9B by 2030
The rising geriatric population, increasing healthcare costs and changing lifestyle are primary factors that have contributed towards market growth. - 8/9/2022
Amneal appoints Deborah Autor to board of directors
Autor has biopharmaceutical industry expertise in quality, regulatory and policy. - 8/9/2022
Southeastern Grocers celebrates back to school season by hosting donation program
Customers are encouraged to round up their grocery bills to support local schools and enjoy savings for the year ahead. - 8/9/2022
Ahold Delhaize reports hike in Q2 sales, raises full-year EPS
While delivering a resilient performance in the second quarter amid inflation and other factors, Ahold Delhaize raised its full-year EPS and free cash flow guidance. - 8/9/2022
Mayne Pharma sells Metrics Contract Services to Catalent for $475M
Metrics Contract Services provides a broad range of services, from drug development to commercial manufacturing, from its facility in Greenville, N.C. - 8/9/2022
CVS Health completes rollout of time-delay safes in 5 western states
All 106 CVS Pharmacy locations across Colorado, Utah, Montana, Idaho and Wyoming are now using time-delay safe technology. - 8/9/2022
Kinney Drugs names James Clapp VP of merchandising, supply chain
Clapp will be responsible for developing and growing Kinney Drugs’ overall retail sales and profitability, and will work across all KPH corporate channels. - 8/8/2022
NACDS amplifies campaign highlighting pharmacy’s value
NACDS’ sustained ‘Pharmacies: The Face of Neighborhood Healthcare’ campaign seeks to prevent a rollback of government policies that have enhanced patients’ access to pharmacies during the pandemic. - 8/8/2022
Kinney Drugs accepting OTC Network payments
More than 1.4 million products are eligible for purchase, including over-the-counter medicines, health-and-wellness products, and in some cases healthy foods. - 8/8/2022
FDA approves Bioeq’s Lucentis biosimilar
Cimerli is the only biosimilar approved for all five Lucentis indications.
